University of Pittsburg Medical Center
Trial Type: Treatment.
This is a phase II clinical trial aimed at evaluating the efficacy of PD-L1 inhibition with atezolizumab in advanced squamous and non-squamous NSCLC patients previously treated with anti-PD-1 therapy with either nivolumab or pembrolizumab.
In order to account for the variability of response kinetics to PD-1 directed therapy, patients will be enrolled in 3 parallel cohorts based on the best overall response to PD-1 directed therapy.
- Cohort 1 (progressive disease)
- Cohort 2 (stable disease with minimum 12 weeks of therapy)
- Cohort 3 (partial to complete response followed by progressive disease)
This study is currently enrolling.